AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Feb 4, 2025
32559_dirs_2025-02-03_b72994e6-0f8b-44fa-9158-8d0ba9a62d2e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-01-30
Reporting Person: Kuriakose Emil (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-30 | Stock Option (Right to Buy) | $4.64 | A | 485000.00 | Acquired | 2035-01-29 | Common Stock (485000.00) | Direct |
Footnotes
F1: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.